11.31

0.27% 0.005

Stoke Therapeutics Inc (STOK)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$11.31

Offen:

$11.26

24-Stunden-Volumen:

8,354

Relative Volume:

0.02

Marktkapitalisierung:

$613.62M

Einnahmen:

$8.78M

Nettoeinkommen (Verlust:

$-104.70M

KGV:

-4.4723

EPS:

-2.53

Netto-Cashflow:

$-82.68M

1W Leistung:

-18.53%

1M Leistung:

-9.86%

6M Leistung:

-26.12%

1J Leistung:

+190.77%

1-Tages-Spanne:

$11.21

$11.42

1-Wochen-Bereich:

$11.08

$13.95

52-Wochen-Spanne:

$3.77

$17.58

Stoke Therapeutics Inc Stock (STOK) Company Profile

Firmenname

Stoke Therapeutics Inc

Sektor

Healthcare (1195)

Branche

Biotechnology (683)

Telefon

781-430-8200

Adresse

45 WIGGINS AVENUE, BEDFORD, MA

Mitarbeiter

110

Twitter

@stoketx

Nächster Verdiensttermin

2024-11-05

Neueste SEC-Einreichungen

STOK's Discussions on Twitter

Vergleichen Sie STOK mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
STOK	11.34	613.62M	8.78M	-104.70M	-82.68M	-2.53
VRTX	447.65	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	741.99	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	588.27	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	249.68	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.49	24.49B	3.30B	-501.07M	1.03B	11.54

Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-10-14	Fortgesetzt	Leerink Partners	Outperform
2024-03-26	Hochstufung	TD Cowen	Market Perform → Outperform
2023-11-20	Fortgesetzt	JP Morgan	Neutral
2023-07-25	Herabstufung	TD Cowen	Outperform → Market Perform
2023-05-01	Hochstufung	BofA Securities	Underperform → Neutral
2023-04-26	Fortgesetzt	Canaccord Genuity	Buy
2023-01-06	Herabstufung	BofA Securities	Buy → Underperform
2022-10-24	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2022-01-31	Eingeleitet	Jefferies	Buy
2021-12-03	Eingeleitet	BofA Securities	Buy
2021-11-22	Hochstufung	JP Morgan	Neutral → Overweight
2021-05-18	Eingeleitet	UBS	Neutral
2021-05-10	Hochstufung	Wedbush	Neutral → Outperform
2021-04-26	Fortgesetzt	Credit Suisse	Outperform
2021-02-10	Herabstufung	Wedbush	Outperform → Neutral
2020-12-15	Fortgesetzt	H.C. Wainwright	Buy
2020-12-11	Bestätigt	Needham	Buy
2020-10-23	Eingeleitet	Cantor Fitzgerald	Overweight
2020-09-29	Fortgesetzt	JP Morgan	Neutral
2020-09-29	Eingeleitet	Needham	Buy
2019-12-18	Eingeleitet	Wedbush	Outperform
2019-11-12	Eingeleitet	BTIG Research	Buy
2019-10-25	Eingeleitet	H.C. Wainwright	Buy
2019-07-15	Eingeleitet	Canaccord Genuity	Buy
2019-07-15	Eingeleitet	Cowen	Outperform
2019-07-15	Eingeleitet	Credit Suisse	Outperform
2019-07-15	Eingeleitet	JP Morgan	Overweight

Alle ansehen

Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten

Nov 20, 2024

Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Zacks Investment Research

Nov 20, 2024

Nov 17, 2024

Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of “Buy” by Brokerages - Defense World

Nov 17, 2024

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $20.83 Average PT from Analysts - MarketBeat

Nov 17, 2024

Los Angeles Capital Management LLC Grows Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat

Nov 15, 2024

Nov 14, 2024

Lynx1 Capital Management LP's Strategic Acquisition in Stoke The - GuruFocus.com

Nov 14, 2024

Nov 12, 2024

Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade - MSN

Nov 12, 2024

Nov 09, 2024

FY2024 EPS Forecast for Stoke Therapeutics Lifted by Analyst - Defense World

Nov 09, 2024

Nov 08, 2024

Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts - Simply Wall St

Nov 08, 2024

Wedbush Lifts Earnings Estimates for Stoke Therapeutics - MarketBeat

Nov 08, 2024

Research Analysts Offer Predictions for STOK FY2024 Earnings - MarketBeat

Nov 08, 2024

Research Analysts Set Expectations for STOK FY2024 Earnings - MarketBeat

Nov 08, 2024

Nov 06, 2024

Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Needham & Company LLC - MarketBeat

Nov 06, 2024

Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts - Simply Wall St

Nov 06, 2024

Need To Know: Analysts Are Much More Bullish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenues - Yahoo Finance

Nov 06, 2024

Stoke Therapeutics' (STOK) Buy Rating Reiterated at HC Wainwright - MarketBeat

Nov 06, 2024

Nov 05, 2024

Stoke Therapeutics Reports Q3 Results, Focuses on Phase 3 Study - TipRanks

Nov 05, 2024

Stoke Therapeutics (NASDAQ:STOK) Trading Down 4.1%Time to Sell? - MarketBeat

Nov 05, 2024

Stoke Therapeutics earnings beat by $0.07, revenue topped estimates - Investing.com Canada

Nov 05, 2024